ATROPOS: Survival Analysis of ICI-associated Myocarditis

ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M). The study evaluates whether immunosuppressive treatment strategies, including first-line glucocorticoids and subsequent second-line immunosuppressants, are associated with overall mortality, and whether these associations vary according to myocarditis severity. The target number of cases to be included is 1500 spanning from at least 160 centers, located in at least 18 countries. Analyses will adjust for clinically relevant confounders and may use time-dependent survival models where appropriate.

NCT Number	NCT07633587
Lead Sponsor	Groupe Hospitalier Pitie-Salpetriere Collaborators: Vanderbilt University Medical Center
Conditions	Immune Checkpoint Inhibitor-associated Myocarditis
Enrollment	1,500 participants
Start Date	2026-05-20
Primary Completion	2027-10-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-10